Internal Medicine, Hematology & Oncology · Mentor, OH
NPI
1639490469
Since 2010
Specialty
Internal Medicine, Hematology & Oncology
Code 207RH0003X
Group practices
1
Medicare group memberships
Hospitals
5
Hospital affiliations
9485 Mentor Ave, Suite 3
Mentor, OH, 44060
Phone (440) 205-5755
Groups this clinician bills Medicare through
Medicare paid, 2024
$71K
1,228 services
Medicare patients, 2024
311
Average age 75
Drug cost, 2024
$4.0M
1,861 prescriptions
Company payments, 2025
$3,630
From 3 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Daniel R Silbiger was code G2211 (visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's), 245 times for 108 patients. In total Daniel R Silbiger billed 1,228 services in 15 codes, and Medicare paid $71K.
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2020-12-21.
| Code | Setting | Services | Patients | Paid per service | Medicare paid |
|---|---|---|---|---|---|
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 245 | 108 | $12.39 | $3,035 |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Facility | 221 | 93 | $12.49 | $2,760 |
| 99215 Office E&M - Established | Office | 188 | 73 | $102.34 | $19K |
| 99215 Office E&M - Established | Facility | 184 | 56 | $103.39 | $19K |
| 99214 Office E&M - Established | Office | 132 | 90 | $64.70 | $8,541 |
| 99214 Office E&M - Established | Facility | 90 | 61 | $61.01 | $5,491 |
| 99233 Hospital E&M - Subsequent | Facility | 35 | 23 | $83.65 | $2,928 |
| 99213 Office E&M - Established | Office | 31 | 30 | $28.97 | $898 |
| 99205 Office E&M - New | Facility | 24 | 24 | $132.88 | $3,189 |
| 99213 Office E&M - Established | Facility | 21 | 19 | $40.75 | $856 |
| 99205 Office E&M - New | Office | 15 | 15 | $115.36 | $1,730 |
By year: 2022 $80K for 1,024 services; 2023 $73K for 885 services; 2024 $71K for 1,228 services.
Medicare prescription drug claims, 2024
In 2024, the drug Daniel R Silbiger prescribed most often to Medicare patients was Anastrozole, with 451 prescriptions and refills. In total Daniel R Silbiger wrote 1,861 Medicare prescriptions that cost $4.0M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Anastrozole Generic | 451 | 1,096 | 145 | $8,058 |
| Prednisone Generic | 117 | 155 | 32 | $385 |
| Ondansetron Hcl Generic | 66 | 69 | 42 | $1,080 |
| Levothyroxine Sodium Generic | 62 | 112 | 14 | $554 |
| Eliquis Apixaban | 62 | 100 | 14 | $58K |
| Ibrance Palbociclib | 62 | 62 | Under 11 | $876K |
| Letrozole Generic | 58 | 159 | 25 | $1,408 |
| Gabapentin Generic | 57 | 93 | 20 | $596 |
| Abiraterone Acetate Generic | 51 | 59 | Under 11 | $80K |
| Potassium Chloride Generic | 38 | 72 | 18 | $514 |
| Prochlorperazine Maleate Generic | 35 | 35 | 23 | $451 |
| Acyclovir Generic | 32 | 40 | Under 11 | $456 |
| Lorazepam Generic | 32 | 32 | 12 | $107 |
| Omeprazole Generic | 32 | 58 | Under 11 | $308 |
| Hydroxyurea Generic | 29 | 82 | Under 11 | $539 |
Brand drugs: 348 claims; generic drugs: 1,513 claims; opioid claims: 55.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Daniel R Silbiger $3,630 ($3,630 in general payments such as food, travel and fees) from 3 companies. The largest payer was AstraZeneca Pharmaceuticals LP with $2,345.
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.